title: Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.
abstract: BACKGROUND
  The potential benefits of haematopoietic stem-cell transplantation are tempered by the depletion of T-cells accompanying this procedure. We used a new technique which quantifies the excisional DNA products of T-cell-receptor (TCR) gene rearrangement to measure thymic output directly in patients with multiple myeloma, and thus assessed the contribution of the thymus to immune recovery after transplantation.
  
  
  METHODS
  We studied 40 patients, 34-66 years of age, who had been randomly assigned myeloablative chemotherapy and autologous peripheral-blood haematopoietic stem-cell transplantation with unmanipulated grafts or grafts enriched for CD34 stem cells. CD4 and CD8 T-cell counts were measured, thymic output was estimated serially until 2 years after transplantation, and percentages of naive T-cells were measured.
  
  
  RESULTS
  The production of substantial numbers of new naive T cells by the thymus could be detected by 100 days post-transplant; there was a significant inverse relation between age and recovery of new T cells. In the CD34-unselected group, numbers of TCR-rearrangement excision circles returned to baseline after 2 years, whereas in the CD34-selected group, numbers at 2 years were significantly higher than both baseline numbers (p=0.004), and 2-year numbers in the unselected group (p=0.046). Increased thymic output correlated with, and was predictive of, increased naive T-cell numbers and broader T-cell-receptor repertoires.
  
  
  CONCLUSIONS
  Our results provide evidence that the adult thymus contributes more substantially to immune reconstitution after haematopoietic stem-cell transplantation than was previously thought, and therefore could be a target for therapeutic intervention.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75390, USA. daniel.douek@mednet.swmed.edu
authors.forename: D C
authors.initials: DC
authors.lastname: Douek
authors.forename: R A
authors.initials: RA
authors.lastname: Vescio
authors.forename: M R
authors.initials: MR
authors.lastname: Betts
authors.forename: J M
authors.initials: JM
authors.lastname: Brenchley
authors.forename: B J
authors.initials: BJ
authors.lastname: Hill
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: J R
authors.initials: JR
authors.lastname: Berenson
authors.forename: R H
authors.initials: RH
authors.lastname: Collins
authors.forename: R A
authors.initials: RA
authors.lastname: Koup
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015329:Gene Rearrangement, T-Lymphocyte; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018655:Lymphocyte Count; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D019653:Myeloablative Agonists / Q000008:administration & dosage; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes; D013950:Thymus Gland / Q000276:immunology*; D019172:Transplantation Conditioning
chemical_list: D015703:Antigens, CD; D019653:Myeloablative Agonists; D011948:Receptors, Antigen, T-Cell; D016179:Granulocyte Colony-Stimulating Factor